343 related articles for article (PubMed ID: 22065672)
1. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans.
Caskey M; Lefebvre F; Filali-Mouhim A; Cameron MJ; Goulet JP; Haddad EK; Breton G; Trumpfheller C; Pollak S; Shimeliovich I; Duque-Alarcon A; Pan L; Nelkenbaum A; Salazar AM; Schlesinger SJ; Steinman RM; Sékaly RP
J Exp Med; 2011 Nov; 208(12):2357-66. PubMed ID: 22065672
[TBL] [Abstract][Full Text] [Related]
2. Activation of toll-like receptor signaling pathway for protection against influenza virus infection.
Wong JP; Christopher ME; Viswanathan S; Karpoff N; Dai X; Das D; Sun LQ; Wang M; Salazar AM
Vaccine; 2009 May; 27(25-26):3481-3. PubMed ID: 19200852
[TBL] [Abstract][Full Text] [Related]
3. Learning vaccinology from viral infections.
Ahmed R; Pulendran B
J Exp Med; 2011 Nov; 208(12):2347-9. PubMed ID: 22110181
[TBL] [Abstract][Full Text] [Related]
4. Novel antiviral therapeutics to control foot-and-mouth disease.
Dias CC; Moraes MP; Weiss M; Diaz-San Segundo F; Perez-Martin E; Salazar AM; de los Santos T; Grubman MJ
J Interferon Cytokine Res; 2012 Oct; 32(10):462-73. PubMed ID: 22924938
[TBL] [Abstract][Full Text] [Related]
5. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H
J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916
[TBL] [Abstract][Full Text] [Related]
6. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs.
Ammi R; De Waele J; Willemen Y; Van Brussel I; Schrijvers DM; Lion E; Smits EL
Pharmacol Ther; 2015 Feb; 146():120-31. PubMed ID: 25281915
[TBL] [Abstract][Full Text] [Related]
7. Poly-ICLC, a multi-functional immune modulator for treating cancer.
Sultan H; Salazar AM; Celis E
Semin Immunol; 2020 Jun; 49():101414. PubMed ID: 33011064
[TBL] [Abstract][Full Text] [Related]
8. Poly-ICLC preconditioning protects the blood-brain barrier against ischemic injury in vitro through type I interferon signaling.
Gesuete R; Packard AE; Vartanian KB; Conrad VK; Stevens SL; Bahjat FR; Yang T; Stenzel-Poore MP
J Neurochem; 2012 Nov; 123 Suppl 2(Suppl 2):75-85. PubMed ID: 23050645
[TBL] [Abstract][Full Text] [Related]
9. Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial.
Saxena M; Sabado RL; La Mar M; Mohri H; Salazar AM; Dong H; Correa Da Rosa J; Markowitz M; Bhardwaj N; Miller E
Front Immunol; 2019; 10():725. PubMed ID: 31024557
[No Abstract] [Full Text] [Related]
10. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity.
Trumpfheller C; Longhi MP; Caskey M; Idoyaga J; Bozzacco L; Keler T; Schlesinger SJ; Steinman RM
J Intern Med; 2012 Feb; 271(2):183-92. PubMed ID: 22126373
[TBL] [Abstract][Full Text] [Related]
11. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
Ishikawa T; Kageyama S; Miyahara Y; Okayama T; Kokura S; Wang L; Sato E; Yagita H; Itoh Y; Shiku H
Cancer Immunol Immunother; 2021 Nov; 70(11):3081-3091. PubMed ID: 33751208
[TBL] [Abstract][Full Text] [Related]
12. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners.
Zhu X; Fallert-Junecko BA; Fujita M; Ueda R; Kohanbash G; Kastenhuber ER; McDonald HA; Liu Y; Kalinski P; Reinhart TA; Salazar AM; Okada H
Cancer Immunol Immunother; 2010 Sep; 59(9):1401-9. PubMed ID: 20549206
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine.
He LZ; Weidlick J; Sisson C; Marsh HC; Keler T
Cell Mol Immunol; 2015 Nov; 12(6):719-28. PubMed ID: 25345808
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.
Kyi C; Roudko V; Sabado R; Saenger Y; Loging W; Mandeli J; Thin TH; Lehrer D; Donovan M; Posner M; Misiukiewicz K; Greenbaum B; Salazar A; Friedlander P; Bhardwaj N
Clin Cancer Res; 2018 Oct; 24(20):4937-4948. PubMed ID: 29950349
[No Abstract] [Full Text] [Related]
15. Prophylactic, therapeutic and immune enhancement effect of liposome-encapsulated PolyICLC on highly pathogenic H5N1 influenza infection.
Li Y; Hu Y; Jin Y; Zhang G; Wong J; Sun LQ; Wang M
J Gene Med; 2011 Jan; 13(1):60-72. PubMed ID: 21259409
[TBL] [Abstract][Full Text] [Related]
16. Enhanced induction of plasma interferon after subcutaneous administration in rabbits of poly ICLC with albumin.
Pessina GP; Muscettola M; Paulesu L; Bocci V
J Biol Regul Homeost Agents; 1989; 3(3):118-21. PubMed ID: 2483023
[TBL] [Abstract][Full Text] [Related]
17. Poly ICLC increases the potency of a replication-defective human adenovirus vectored foot-and-mouth disease vaccine.
Diaz-San Segundo F; Dias CC; Moraes MP; Weiss M; Perez-Martin E; Salazar AM; Grubman MJ; de Los Santos T
Virology; 2014 Nov; 468-470():283-292. PubMed ID: 25216089
[TBL] [Abstract][Full Text] [Related]
18. Vaccine adjuvant uses of poly-IC and derivatives.
Martins KA; Bavari S; Salazar AM
Expert Rev Vaccines; 2015 Mar; 14(3):447-59. PubMed ID: 25308798
[TBL] [Abstract][Full Text] [Related]
19. Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model.
Boukhvalova MS; Sotomayor TB; Point RC; Pletneva LM; Prince GA; Blanco JC
J Interferon Cytokine Res; 2010 Apr; 30(4):229-42. PubMed ID: 20038196
[TBL] [Abstract][Full Text] [Related]
20. Double-Stranded RNA Immunomodulators in Prostate Cancer.
Salazar AM; Celis E
Urol Clin North Am; 2020 Nov; 47(4S):e1-e8. PubMed ID: 33446322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
